myl

Mylan received final approval form the FDA for the Budesonide capsules on May 16, 2011. It is the generic version of AstraZeneca's Entocort EC capsules. It is the first generic version of the drug to be introduced in the U.S.

Budesonide had sales in the U.S.

Mylan Inc. (NASDAQ:MYL) announced today that the U.S. District Court for Delaware has found that the company's Budesonide Capsules do not infringe upon AstraZeneca's (NYSE:AZN) patent for its Entocort EC capsules, a treatment for

The company sees 2011 EPS of $1.90 to $2.10, vs. consensus estimates of $1.63 billion.

Mylan has a potential upside of 5.8% based on a current price of $24.84 and an average consensus analyst price target of $26.29.

Mylan(NYSE:MYL) reported Q1 EPS of $0.44, in line with consensus estimates. Revenues for the quarter rose 12.4% year-over-year to $1.44 billion, ahead of consensus estimates of $1.43 billion.

In its complaint, Mylan said it and other generic drug companies should be permitted to enter the market as soon as Lipitor's patent expires, according to the report.

Mylan shares are up 0.7%.

Shares of Mylan Inc. (MYL) are higher after Bloomberg reported that the company sued the US Food and Drug Administration in a move to block India's Ranbaxy Laboratories exclusive rights to sell a generic version of Lipitor, Pfizer

Mylan's new drug is based on Retrovir Tablets by ViiV Healthcare.

Mylan Inc (NASDAQ:MYL) announced its subsidiary Matrix Laboratories has received final approval from the U.S. Food and Drug Administration for its new drug Zidovudine, under the President's Emergency Plan for AIDS Relief (PEPFAR).

Health care shares are higher Monday. Bloomberg is reporting that a high school teacher in Tasmania is suing Johnson & Johnson over an implanted hip-replacement device that stopped selling in Australia due to defects. Meanwhil

Matrix has received final approval from the FDA for Gabapentin Capsules. The drug is a generic version of Pfizer's Neurontin. It's used to treat a painful complication of shingles.

Matrix's Gabapentin had U.S. sales of about $300 million last year. The drug-maker is launching this product immediately.

Mylan Inc. (MYL) is up nearly 3% Monday, on news from its subsidiary, Matrix Laboratories.

For 2011, the company sees revenues of $6.1 to $6.4 billion, vs. consensus estimates of $6.1 billion.

Robert J. Coury, Mylan's Chairman and Chief Executive Officer stated: "I am very pleased with our performance in 2010, as we delivered solid revenue growth of 8% over the prior year and strong earnings per share growth of 24%.

Mylan (NYSE:MYL) reported Q4 EPS of $0.45, in line with consensus estimates. Revenues for the quarter rose 6% year-over-year to $1.43 billion, missing consensus estimates $1.46 billion.

Texas Attorney General Greg Abbott said he resolved a state enforcement action against Mylan Laboratories, which was charged with inaccurately reporting drug prices to the Texas Medicaid program. Under the agreement, Mylan must pa

Officials from Mylan Inc. (NASDAQ:MYL) are ready to settle a U.S. government lawsuit regarding Medicaid reimbursements from healthcare industry employees, Bloomberg reports Monday.
Mylan has agreed to pay $65 million to sett